MetaVia Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will present new Phase 1 and pre-clinical data on DA-1726, a novel, dual ...

According to observers, SBF’s chances of getting a fresh trial are slim, judging by the pointed questions of an appellate ...

The risks are not theoretical. On September 26, 2025, three U.K. campaigning groups published a joint letter sent to the CMA ...

CareRx Corporation ( CRRX:CA) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST ...

Mean weight loss of 19.2%I at 6 mg with no plateau and favorable safety profile in 48-week Phase 3 clinical trial –– Data builds on previously ...

A Glocester, Rhode Island farm discovered their well water is contaminated with PFAS, or "forever chemicals," at levels ten ...

Details of the novel pharmacokinetic assay for measuring SAB-142.

LAWRENCEVILLE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it will ...

The company’s financial performance remains highly sensitive to ZAR/USD exchange rate movements, with the presentation noting that a ZAR1 movement against the USD equates to approximately $8-10 ...

Prezent, a startup that offers an AI-powered presentation builder to enterprises, said today that it has raised $30 million in funding led by Multiplier Capital, Greycroft, and Nomura Strategic ...

and promoting positive health economics. The Company seeks to drive growth by leveraging its expertise in sales and commercialization of its broad portfolio of medical technology products, mainly in ...